Stocks · US
PEN
XNYS
Penumbra, Inc.
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E77.78x
P/B8.16x
P/S8.30x
EPS$4.08
ROE10.49%
ROA8.13%
Dividend yield0.00%
EV/EBITDA60.19x
Debt/Equity0.01
Free cash flow$216M
Returns and 52-week range
1W-0.57%
1M-1.59%
3M-0.07%
6M-3.91%
1Y+23.82%
YTD+2.47%
52W high$362.41
52W low$221.26
From 52W high-12.52%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Baxter International Inc. | $12.5B | — | 2.02 | -5.69% |
| Halozyme Therapeutics, Inc. | $12.3B | 29.72 | 85.64 | -0.43% |
| 10X 지노믹스 | $12.7B | — | 15.43 | +28.75% |
| BrightSpring Health Services, Inc. Common Stock | $12.3B | 33.52 | 5.99 | +4.97% |
| BridgeBio Pharma, Inc. Common Stock | $12.9B | — | — | -10.53% |
| Madrigal Pharmaceuticals, Inc. Common Stock | $11.4B | — | 21.78 | -8.25% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.